The inventors have developed a biomarker application based on thromboxane receptor β (TPβ), which identifies patients with various stages of bladder cancers (invasive, superficial, or metastatic). TPβ proteins are overexpressed in common bladder tumor tissue but not normal human cells. Human urine samples of patients positive for various degrees of bladder cancer confirm sensitivity approaching 93%, with 100% specificity. The detection of these proteins provide a novel, non-invasive early diagnostic method and for follow up monitoring in case of recurrence.
Bladder cancer is the fifth most common cancer in U.S. (4.6%). When detected early stage, it has a 94% survival rate. Survival rate drops to 46% after spreading to surrounding region, and declines to 6% after metastases. The gold standard for diagnosing via cystoscopy, however this is invasive, costly and is limited to interpretation bias. Other diagnostic assays, such as cystoscopy and fluorescent in situ hybridization (FISH), have limited sensitivity (50-70%). Improved sensitivity and specificity for bladder cancer would significantly increase patient survival. Also given a high recurrence rate, an easy to administer follow up procedure would be an effective clinical application in healthcare.
Highly specific and selective early detection and progressive monitoring of bladder cancer
Key Words: Bladder cancer, urine analysis, assay, specificity, selectivity, diagnostic, thromboxane receptor
Inventors: O. Moussa, D. Watson, P. Halushka
Patent Status: US Patent 8,101,371
MUSC-FRD Technology ID: P0804